Inhibikase Therapeutics (IKT) Asset Utilization Ratio (2021 - 2024)
Historic Asset Utilization Ratio for Inhibikase Therapeutics (IKT) over the last 4 years, with Q3 2024 value amounting to 0.0.
- Inhibikase Therapeutics' Asset Utilization Ratio fell 9999.91% to 0.0 in Q3 2024 from the same period last year, while for Sep 2024 it was 0.0, marking a year-over-year decrease of 9999.91%. This contributed to the annual value of 0.01 for FY2023, which is 26064.89% up from last year.
- Inhibikase Therapeutics' Asset Utilization Ratio amounted to 0.0 in Q3 2024, which was down 9999.91% from 0.01 recorded in Q2 2024.
- Inhibikase Therapeutics' Asset Utilization Ratio's 5-year high stood at 0.14 during Q1 2021, with a 5-year trough of 0.0 in Q3 2024.
- Its 4-year average for Asset Utilization Ratio is 0.03, with a median of 0.02 in 2024.
- In the last 5 years, Inhibikase Therapeutics' Asset Utilization Ratio soared by 71541.88% in 2023 and then crashed by 9999.91% in 2024.
- Inhibikase Therapeutics' Asset Utilization Ratio (Quarter) stood at 0.07 in 2021, then plummeted by 93.43% to 0.0 in 2022, then surged by 248.72% to 0.02 in 2023, then tumbled by 100.0% to 0.0 in 2024.
- Its last three reported values are 0.0 in Q3 2024, 0.01 for Q2 2024, and 0.02 during Q1 2024.